BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7597306)

  • 21. Interferon alpha-2a in cutaneous T-cell lymphoma.
    Vegna ML; Papa G; Defazio D; Pisani F; Coppola G; De Pità O; Puddu P; Ferranti G; Simoni R; Mandelli F
    Eur J Haematol Suppl; 1990; 52():32-5. PubMed ID: 2279544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
    Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
    Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Juvenile mycosis fungoides with large-cell transformation: Successful treatment with psoralen with ultraviolet A light, interferon-alfa, and localized radiation.
    Chan WH; Lewis DJ; Hinojosa T; Curry JL; Duvic M
    Pediatr Dermatol; 2018 Jan; 35(1):e13-e16. PubMed ID: 29159918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma.
    Marolleau JP; Baccard M; Flageul B; Rybojad M; Laroche L; Vérola O; Brandely M; Morel P; Gisselbrecht C
    Arch Dermatol; 1995 May; 131(5):574-9. PubMed ID: 7741545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
    Foss FM; Ihde DC; Linnoila IR; Fischmann AB; Schechter GP; Cotelingam JD; Steinberg SM; Ghosh BC; Stocker JL; Bastian A
    J Clin Oncol; 1994 Oct; 12(10):2051-9. PubMed ID: 7931473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon-alpha (INF-alpha) and etretinate in the treatment of mycosis fungoides.
    Torii H; Kaneko T; Matsuyama T; Nakanishi H; Harada S
    J Dermatol; 1994 Oct; 21(10):767-70. PubMed ID: 7798436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Photochemotherapy in cutaneous T cell lymphoma and parapsoriasis en plaques. Long-term follow-up in forty-three patients.
    Rosenbaum MM; Roenigk HH; Caro WA; Esker A
    J Am Acad Dermatol; 1985 Oct; 13(4):613-22. PubMed ID: 3878369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Interferon-alpha and PUVA therapy for mycosis fungoides].
    Marschalkó M; Kovács J; Somlai B; Berecz M; Hídvégi B; Hársing J; Désaknai M; Horváth A
    Orv Hetil; 2001 Sep; 142(37):2021-3. PubMed ID: 11582733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic alternatives in cutaneous T-cell lymphoma.
    Holloway KB; Flowers FP; Ramos-Caro FA
    J Am Acad Dermatol; 1992 Sep; 27(3):367-78. PubMed ID: 1383293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways.
    Wozniak MB; Tracey L; Ortiz-Romero PL; Montes S; Alvarez M; Fraga J; Fernández Herrera J; Vidal S; Rodriguez-Peralto JL; Piris MA; Villuendas Deceased R
    Br J Dermatol; 2009 Jan; 160(1):92-102. PubMed ID: 18945306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon alfa-2a maintenance after salvage autologous stem cell transplantation in atypical mycosis fungoides with central nervous system involvement.
    Doerschner M; Pekar-Lukacs A; Messerli-Odermatt O; Dommann-Scherrer C; Rütti M; Müller AM; Nair G; Kamarachev J; Kerl K; Beer M; Messerli M; Frauenknecht K; Haralambieva E; Hoetzenecker W; French LE; Guenova E
    Br J Dermatol; 2019 Dec; 181(6):1296-1302. PubMed ID: 30565216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma.
    Spaccarelli N; Rook AH
    Dermatol Clin; 2015 Oct; 33(4):731-45. PubMed ID: 26433845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids.
    Knobler RM; Trautinger F; Radaszkiewicz T; Kokoschka EM; Micksche M
    J Am Acad Dermatol; 1991 Feb; 24(2 Pt 1):247-52. PubMed ID: 2007670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma.
    Hüsken AC; Tsianakas A; Hensen P; Nashan D; Loquai C; Beissert S; Luger TA; Sunderkötter C; Schiller M
    J Eur Acad Dermatol Venereol; 2012 Jan; 26(1):71-8. PubMed ID: 22168776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferons for cutaneous T-cell lymphoma monotherapy or combination with PUVA.
    Roenigk HH; Kuzel T; Rosen S
    Australas J Dermatol; 1993; 34(1):13-5. PubMed ID: 8240181
    [No Abstract]   [Full Text] [Related]  

  • 37. Intramuscular low dose alpha-2B interferon and etretinate for treatment of mycosis fungoides.
    Altomare GF; Capella GL; Pigatto PD; Finzi AF
    Int J Dermatol; 1993 Feb; 32(2):138-41. PubMed ID: 8440560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon in the treatment of cutaneous T-cell lymphoma.
    Olsen EA
    Dermatol Ther; 2003; 16(4):311-21. PubMed ID: 14686974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Alpha interferon in therapy of non-Hodgkin's lymphoma].
    Freund M; Hanauske AR
    Onkologie; 1990 Dec; 13(6):424-8. PubMed ID: 2092278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Follicular mycosis fungoides.
    Klemke CD; Dippel E; Assaf C; Hummel M; Stein H; Goerdt S; Orfanos CE
    Br J Dermatol; 1999 Jul; 141(1):137-40. PubMed ID: 10417530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.